NCT03483103 · OUTCOME

Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: 10^9 cells/L
Interval / dispersion: Standard Deviation
Time frame: Baseline and Day 29

What was measured

Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion.

Analysis population: All participants who received at least one JCAR017 infusion evaluable for hematology laboratory tests

Groups in this outcome

Lisocabtagene Maraleucel (JCAR017)

Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Lisocabtagene Maraleucel (JCAR017)	59

Reported measurements

Leukocytes

Values in 10^9 cells/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Lisocabtagene Maraleucel (JCAR017)	0.921	3.8562	Not reported	Not reported	Not reported

Lymphocytes

Values in 10^9 cells/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Lisocabtagene Maraleucel (JCAR017)	0.537	0.5953	Not reported	Not reported	Not reported

Neutrophils

Values in 10^9 cells/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Lisocabtagene Maraleucel (JCAR017)	-0.216	3.4010	Not reported	Not reported	Not reported

Platelets

Values in 10^9 cells/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Lisocabtagene Maraleucel (JCAR017)	-61.6	96.55	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
3.8562
value
0.921
title
Leukocytes
categories
measurements
group Id
OG000
spread
0.5953
value
0.537
title
Lymphocytes
categories
measurements
group Id
OG000
spread
3.4010
value
-0.216
title
Neutrophils
categories
measurements
group Id
OG000
spread
96.55
value
-61.6
title
Platelets

denoms

counts
group Id
OG000
value
59
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
id
OG000
title
Lisocabtagene Maraleucel (JCAR017)

param Type

MEAN

population Description

All participants who received at least one JCAR017 infusion evaluable for hematology laboratory tests

reporting Status

POSTED

time Frame

Baseline and Day 29

title

Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets

type

SECONDARY

unit Of Measure

10^9 cells/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice